Home
Conditions
Histiocytic Disorders, Malignant

Clinical trial condition

Histiocytic Disorders, Malignant

Explore clinical trials studying Histiocytic Disorders, Malignant. Study availability and eligibility vary by location and protocol.

271 public trials 44 recruiting studies

Refine in advanced search Browse all conditions

Histiocytic Disorders, Malignant trial results

Not yet recruiting

Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics

NCT07748364

Conditions: Dendritic Cell Sarcoma, Interdigitating, Disease Attributes, Hemic and Lymphatic Diseases, +18 more
Locations: Icahn School of Medicine at Mount Sinai New York, United States

View Trial Details

Not yet recruiting

Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma

NCT07677813

Conditions: DLBCL - Diffuse Large B Cell Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Hemic and Lymphatic Diseases, +5 more
Locations: The First Bethune Hospital of Jilin University Changchun, Jilin, China

View Trial Details

Not yet recruiting

Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP

NCT07552324

Conditions: DHL, DLBCL - Diffuse Large B Cell Lymphoma, Dendritic Cell Sarcoma, Interdigitating, +7 more
Locations: Not specified

View Trial Details

Not yet recruiting

A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyping

NCT07511114

Conditions: DLBCL - Diffuse Large B Cell Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Double Expressor Lymphoma, +6 more
Locations: No. 197 Ruijin 2nd Road, Huangpu District, Shanghai, Shanghai, Shanghai Shanghai, China

View Trial Details

Not yet recruiting

Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma

NCT07472621

Conditions: DLBCL - Diffuse Large B Cell Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Hemic and Lymphatic Diseases, +5 more
Locations: Henan cancer hospital Zhengzhou, Henan, China

View Trial Details

Not yet recruiting

Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL

NCT07389356

Conditions: DLBCL - Diffuse Large B Cell Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Hemic and Lymphatic Diseases, +5 more
Locations: Not specified

View Trial Details

Not yet recruiting

Glofitamab Combined With CAR-T Therapy in R/R DLBCL

NCT07326371

Conditions: DLBCL - Diffuse Large B Cell Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Hemic and Lymphatic Diseases, +5 more
Locations: Not specified

View Trial Details

Not yet recruiting

Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

NCT07231250

Conditions: Bispecific Antibody, Chemo-free Therapy, DLBCL - Diffuse Large B Cell Lymphoma, +7 more
Locations: Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China

View Trial Details

Not yet recruiting

ImmunoMRI for Assessment of Tumor-associated Macrophages

NCT07066436

Conditions: DLBCL - Diffuse Large B Cell Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Hemic and Lymphatic Diseases, +5 more
Locations: Medical University of Vienna Vienna, State of Vienna, Austria

View Trial Details

Not yet recruiting

A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1

NCT07034508

Conditions: DLBCL - Diffuse Large B Cell Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Hemic and Lymphatic Diseases, +5 more
Locations: China Institute of Hematology and Blood Diseases Hospital Tianjin, China

View Trial Details

Histiocytic Disorders, Malignant

Histiocytic Disorders, Malignant trial results

Related conditions